Effect of prior cancer on outcomes in advanced lung cancer: Implications for clinical trial eligibility and accrual

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  Laccetti, Andrew L ^a   Pruitt, Sandi L ^b,c   Xuan, Lei ^b   Halm, Ethan A ^a,b,c   Gerber, David E ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIOR CANCER; PRIORITY JOURNAL; PROPENSITY SCORE; VERY ELDERLY; AGE; CANCER REGISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MEDICARE; MORTALITY; ODDS RATIO; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEDICARE; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84930726124     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv002     Document Type: Article

References (51)

1. Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007;109(3):465-476.
2. Friedman MA, Cain DF. National Cancer Institute sponsored cooperative clinical trials. Cancer. 1990;65(10 Suppl):2376-2382.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726.
4. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728-1733.
5. Lemieux J, Goodwin PJ, Pritchard KI, et al. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol. 2008;26(27):4458-4465.
6. Filion M, Forget G, Brochu O, et al. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment. Clin Trials. 2012;9(5):652-659.
7. Rasco DW, Xie Y, Yan J, et al. The impact of consenter characteristics and experience on patient interest in clinical research. Oncologist. 2009;14(5):468-475.
8. Tournoux C, Katsahian S, Chevret S, et al. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer. 2006;106(2):258-270.
9. Gerber DE, Rasco DW, Skinner CS, et al. Consent timing and experience: modifiable factors that may influence interest in clinical research. J Oncol Pract. 2012;8(2):91-96.
10. Hietanen PS, Aro AR, Holli KA, et al. A short communication course for physicians improves the quality of patient information in a clinical trial. Acta Oncol. 2007;46(1):42-48.
11. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626-4631.
12. Ross S, Grant A, Counsell C, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143-1156.
13. Lee JY, Breaux SR. Accrual of radiotherapy patients to clinical trials. Cancer. 1983;52(6):1014-1016.
14. Scoggins JF, Ramsey SD. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst. 2010;102(17):1371.
15. Denicoff AM, McCaskill-Stevens W, Grubbs SS, et al. The National Cancer Institute-American Society of Clinical Oncology cancer trial accrual symposium: summary and recommendations. J Oncol Pract. 2013;9(6):267-276.
16. Lemieux J, Amireault C, Camden S, et al. Evaluation of factors associated with recruitment in hematological clinical trials: a retrospective cohort study. Hematology. 2010;15(6):373-377.
17. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233-1240.
18. McCusker J, Wax A, Bennett JM. Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry. Am J Clin Oncol. 1982;5(2):227-236.
19. Kotwall CA, Mahoney LJ, Myers RE, et al. Reasons for non-entry in randomized clinical trials for breast cancer: a single institutional study. J Surg Oncol. 1992;50(2):125-129.
20. Gerber DE, Laccetti AL, Xuan L, et al. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106(11):dju302 doi:10.1093/jnci/dju302.
21. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561-570.
22. Aguilo R, Macia F, Porta M, et al. Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. Eur J Cardiothorac Surg. 2008;34(5):1075-1080.
23. Lopez-Encuentra A, Gomez de la Camara A, Rami-Porta R, et al. Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax. 2007;62(5):386-390.
24. Duchateau CS, Stokkel MP. Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. Chest. 2005;127(4):1152-1158.
25. Liu YY, Chen YM, Yen SH, et al. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung Cancer. 2002;35(2):189-194.
26. Massard G, Ducrocq X, Beaufigeau M, et al. Lung cancer following previous extrapulmonary malignancy. Eur J Cardiothorac Surg. 2000;18(5):524-528.
27. Utsumi T, Fujii Y, Takeda S, et al. Clinical study on lung cancer as a second primary cancer. Surg Today 1998;28(5):487-491.
28. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
29. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
30. Attachment A for the SEER-Medicare PEDSF File SEER Research Data Record Description Cases Diagnosed in 1973-2009. SEER-Medicare Technical Support, Information Management Services, Inc. SEER historic stage A, November 2011:76.
31. Coyte A, Morrison DS, McLoone P. Second primary cancer risk-the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer 2014;14:272.
32. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
33. Ahn DH, Mehta N, Yorio JT, et al. Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013;14(6):644-650.
34. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-897.
35. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
36. National Cancer Institute. SEER-Medicare: Calculation of comorbidity weights. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html. Accessed March 20, 2014.
37. Koroukian SM, Dahman B, Copeland G, et al. The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study. Health Serv Res. 2010;45(1):265-282.
38. Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: John Wiley &Sons;2008.
39. Koppe MJ, Zoetmulder FA, van Zandwijk N, et al. The prognostic significance of a previous malignancy in operable non-small cell lung cancer. Lung Cancer. 2001;32(1):47-53.
40. Nandy N, Dasanu CA. Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review. Curr Med Res Opin. 2013;29(9):1055-1065.
41. VanderWalde AM, Hurria A. Second malignancies among elderly survivors of cancer. Oncologist. 2011;16(11):1572-1581.
42. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2020-2026.
43. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
44. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20-37.
45. Smith A, Balar AV, Milowsky MI, Chen RC. Chapter 83-Bladder Cancer. In: Niederhuber JE, (ed). Abeloff's Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Saunders;2014.
46. Pulte D, Gondos A, Brenner H. Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leuk Lymphoma. 2009;50(2):179-186.
47. Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol. 2010;21(10):2107-2111.
48. Varty PP, Delrio P, Boulos PB. Survival in colorectal carcinoma associated with previous extracolonic cancer. Ann R Coll Surg Engl. 1994;76(3):180-184.
49. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540-3546.
50. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65(1):25-32.
51. Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced nonsmall cell lung cancer in a contemporary, diverse population. J Thorac Oncol. 2010;5(10):1529-1535.